TB-500
Dosage Protocol

Add 3.0 mL of bacteriostatic water to the 10 mg vial, yielding a concentration of 3.33 mg/mL. [5] Inject the water slowly along the vial wall to avoid foam formation, then gently swirl (do not shake vigorously) until fully dissolved. [5]

Before reconstitution, store the lyophilized peptide at −20 °C in dry, dark conditions. Once reconstituted, refrigerate at 2–8 °C and do not freeze; avoid repeated freeze-thaw cycles and let the vial warm to room temperature before opening to reduce condensation. [5] Reconstituted vials remain stable for up to 28 days when stored with bacteriostatic water preservative at proper refrigeration temperature. [5]

TB-500 is a synthetic peptide related to thymosin beta-4, a naturally occurring protein involved in actin regulation, cell movement, and tissue-repair biology. It is structurally derived from the naturally occurring 43-amino-acid thymosin beta-4 but differs in composition. [4]

In a rat model of Achilles tendon injury (32 rats in four groups, dosed intraperitoneally for four weeks), TB-500 alone showed the clearest result, with significantly lower Bonar and Movin histopathology scores and a significant biomechanical advantage over controls; the study's own results state that "Combined BPC-157 and TB-500 treatment did not confer additional benefits compared to either agent alone." [3] Independently documented human clinical trial data for TB-500 could not be verified in the sources reviewed for this page. Review literature describes TB-500 as showing "promising but variable effects" in animal models for tissue healing, while noting that human clinical studies were limited, with only modest improvements documented where reported. [2] A separate 2026 review lists TB-500 among regenerative peptides relevant to chronic pain management, while noting that clinical evidence remains limited. [1]

TB-500 is not approved by the FDA for any indication. No FDA-approved TB-500 product exists, there is no approved-label dosage, and it has no entry in Drugs@FDA databases with therapeutic indications or prescribing information. The World Anti-Doping Agency lists thymosin beta-4 and its derivatives, including TB-500, as prohibited substances in sport. [4] This section describes what the cited literature reports; it is not a claim of safety or effectiveness for human use.